Silymarin ameliorates cisplatin-induced nephrotoxicity by downregulating TNF-α and NF-kB and by upregulating IL-10

Abstract

Cisplatin (CP) is one of the antineoplastic agents used to treat many types of cancers. Besides these effects of CP, it causes various side effects such as nephrotoxicity. Inflammation is considered to be one of the main pathogeneses of CP-induced nephrotoxicity. Silymarin (SIL) is a flavonoid with beneficial pharmacological properties such as antioxidant and anti-inflammatory. The current study aimed to investigate the beneficial effects of Silymarin against CP-induced nephrotoxicity. Albino Wistar male rats were randomly divided into four groups (n=7): Control group was administered saline (0.5 ml) for 10 days intraperitoneally (IP), CP group was received CP (a single dose of 8 mg/kg, IP), CP+ SIL group was administered saline (0.5 ml) for 10 days and was received CP (a single dose of 8 mg/kg). To measure the inflammatory response, TNF-α, NF-kB and IL-10 expressions were performed. As a result, TNF-α and NF-kB expressions significantly increased while IL-10 expression decreased in the kidney of the CP group compared to the control group. However, SIL treatment significantly decreased TNF-α and NF-kB expressions and increased IL-10 expression in kidney CP-treated rats. These findings reveal that SIL may ameliorates the CP-induced nephrotoxicity in rats by inducing downregulation of TNF-α and NF-kB expressions and upregulation of IL-10 expression

Keywords

• Cisplatin
• IL-10
• Nephrotoxicity
• NF-kB
• Silymarin
• TNF-α.

References

1. Abdelmeguid, N. E., Chmaisse, H. N., Abou Zeinab, N. S., 2010a. Protective Effect of Silymarin on Cisplatin-induced Nephrotoxicity in Rats. Pak. J. Nutr. 9(7), 1680–5194.
2. Abdelmeguid, N. E, Chmaisse, H. N., Abou Zeinab, N. S., 2010b. Silymarin ameliorates cisplatin-induced hepatotoxicity in rats: histopathological and ultrastructural studies. P. J. B. S. 13(10), 463-479.
3. Bamboat, Z. M., Ocuin, L. M., Balachandran, V. P., Obaid, H., Plitas, G., Dematteo, R. P., 2010. Conventional DCs reduce liver ischemia/reperfusion injury in mice via IL-10 secretion. J. Clin. Invest. 120(2), 559–569.
4. Chen, G. Y., Nunez, G., 2010. Sterile inflammation: sensing and reacting to damage. Nature Reviews Immunology.10, 826–837.
5. Chen, I. S., Chen, Y. C., Chou, C. H., Chuang, R. F., Sheen, L. Y., Chiu, C. H., 2012. Hepatoprotection of silymarin against thioacetamide-induced chronic liver fibrosis. J. Sci. Food Agric. 92(7), 1441–1447.
6. Chen, X., Wei, W., Li, Y., Huang, J., Ci, X., 2019. Hesperetin relieves cisplatin-induced acute kidney injury by mitigating oxidative stress, inflammation and apoptosis. Chemico-Biological Interactions. 308, 269-278.
7. Dasari, S., Tchounwou, P. B., 2014. Cisplatin in cancer therapy: molecular mechanisms of action. European Journal of Pharmacology. 740, 364-378.
8. Gao, L., Liu, M.-M., Zang, H.-M., Ma, Q.-Y., Yang, Q., Jiang, L., Ren, G.-L., Li, H.-D., Wu, W.-F., Wang, J.-N., Wei, B., Liu, X.-Q., Jiang, C., Huang, C., Li, J., Meng, M., 2018.Restoration of E-cadherin by PPBICA protects against cisplatin-induced acute kidney injury by attenuating inflammation and programmed cell death. Laboratory Investigation. 98, 911–923.

9. Gawad, S. H. A., Mohamed, A. A. K., 2010. Silymarin administration protects against cisplatin-induced nephrotoxicity in adult male albino rats. Egypt. J. Histol. 33(4),683-691.
10. Gómez-Sierra, T., Eugenio-Perez, D., Sanchez-Chinchillas, A., Pedraza-Chaverri, J., 2018. Role of food-derived antioxidants against cisplatin induced-nephrotoxicity. Food and Chemical Toxicology. 120, 230-242.
11. Güntürk, İ., Yazici, C., Köse, K., Dağli, F., Yücel, B., Yay, A., 2019. The effect of N-acetylcysteine on inflammation and oxidative stress in cisplatin-induced nephrotoxicity: a rat model. Turk J. Med. Sci. 49, 1789-1799.
12. Jahan, S., Khan, M., Imran, S., Sair, M., 2015. The hepatoprotective role of Silymarin in isoniazid induced liver damage of rabbits. J. Pak. Med. Assoc. 65(6), 620-2.
13. Kim, M. G. Yang, H. N., , Kim, H. W., Jo, S. K., Cho, W. Y., Kim, K. K., 2010. IL-10 mediates rosiglitazone-induced kidney protection in cisplatin nephrotoxicity. J. Korean Med. Sci. 25, 557-63.
14. Kurts, C., Panzer, U., Anders, H. J., Rees, A. J., 2013. The immune system and kidney disease: basic concepts and clinical implications. Nature Reviews Immunology. 13, 738–753.
15. Lamia, S. S., Emran, T., Rikta, J. K., Chowdhury, N. I., Sarker, M., Jain, P., Islam, T., Gias, Z. T., Shill, C., Reza, H. M., 2021. Coenzyme Q10 and Silymarin Reduce CCl 4-Induced Oxidative Stress and Liver and Kidney Injury in Ovariectomized Rats-Implications for Protective Therapy in Chronic Liver and Kidney Diseases. Pathophysiology. 28(1), 50-63.
16. Mercantepe, F., Mercantepe, T., Topcu, A., Yılmaz, A., Tumkaya, L., 2018. Protective effects of amifostine, curcumin, and melatonin against cisplatin-induced acute kidney injury. Naunyn-Schmiedeberg’s Archives of Pharmacology. 391(9), 915–931.
17. Miller, R. P., Tadagavadi, R. K., Ramesh, G., Reeves, W. B., 2010. Mechanisms of Cisplatin Nephrotoxicity. Toxins, 2, 2490–2518.
18. Momeni, A., Hajigholami, A., Geshnizjani, S., Kheiri, S., 2015. Effect of Silymarin in the Prevention of Cisplatin Nephrotoxicity, a Clinical Trial Study. J. Clin. Diagn. Rs. 9(4), 11-13.
19. Ninsontia, C., Pongjit, K., Chaotham, C., Chanvorachote, P., 2011. Silymarin selectively protects human renal cells from cisplatin-induced cell death. Pharmaceutical Biology. 49(10), 1082-1090.
20. Ozkok, A., Edelstein, C. L., 2014. Pathophysiology of Cisplatin-Induced Acute Kidney Injury. https://doi.org/10.1155/2014/967826. BioMed Research International. 2014, ID 967826
21. Parra, E.R., Villalobos, P., Mino, B., Rodriguez-Canales, J., 2018. Comparison of Different Antibody Clones forImmunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Non–Small Cell Lung Carcinoma. Appl. Immunohistochem. Mol. Morphol. 26(2), 83–93.
22. Rabb, H., Griffin, M. D., McKay, D. B., Swaminathan, S., Pickkers, P., Rosner, M. H., Kellum, J. A., Ronco, C., 2016. Inflammation in AKI: Current understanding, key questions, and knowledge gaps. J. Am. Soc. Nephrol. 27(2), 371–379.
23. Ramesh, G., Reeves, W. B., 2004a. Salicylate reduces cisplatin nephrotoxicity by inhibition of tumor necrosis factor-α. Kidney International. 65(2), 490–498.
24. Ramesh, G., Reeves, W. B., 2004b. Inflammatory cytokines in acute renal failure. Kidney International. 66(91), 56–61).
25. Ramezannezhad, P., Nouri, A., Heidarian, E., 2019. Silymarin mitigates diclofenac-induced liver toxicity through inhibition of inflammation and oxidative stress in male rats. Journal of HerbMed Pharmacology. 8(3), 231–237.
26. Ratliff, B. B., Rabadi, M. M., Vasko, R., Yasuda, K., Goligorsky, M. S., 2013. Messengers without Borders: Mediators of Systemic Inflammatory Response in AKI. J. Am. Soc. Nephrol. 24, 529–536.
27. Sánchez-González, P. D., López-Hernández, F. J., Dueñas, M., Prieto, M., Sánchez-López, E., Thomale, J., Ruiz-Ortega, M., López-Novoa, J. M., Morales, A. I., 2017. Differential effect of quercetin on cisplatin-induced toxicity in kidney and tumor tissues. Food and Chemical Toxicology. 107, 226–236.
28. Shahbazi, F., Dashti-Khavidaki, S., Khalili, H., Lessan-Pezeshki, M., 2012. Potential Renoprotective Effects of Silymarin Against Nephrotoxic Drugs: A Review of Literature. J. Pharm. Pharmaceut. Sci. 15(1), 112-123.
29. Sharp, C. N., Doll, M. A., Dupre, T. V., Shah, P. P., Subathra, M., Siow, D., Arteel, G. E., Megyesi, J., Beverly, L. J., Siskind, L. J., 2016. Repeated administration of low-dose cisplatin in mice induces fibrosis. Am. J.Physio. Renal Physiol. 310(6), 560–568.
30. Soetikno, V., Sari, S. D. P., Ul Maknun, L., Sumbung, N. K., Rahmi, D. N. I., Pandhita, B. A. W., Louisa, M., Estuningtyas, A., 2018. Pre-Treatment with Curcumin Ameliorates Cisplatin-Induced Kidney Damage by Suppressing Kidney Inflammation and Apoptosis in Rats. Drug Research. 69(02), 75–82.
31. Tomar, A., Vasisth, S., Khan, S. I., Malik, S., Nag, T. C., Arya, D. S., Bhatia, J., 2017. Galangin ameliorates cisplatin induced nephrotoxicity in vivo by modulation of oxidative stress, apoptosis and inflammation through interplay of MAPK signaling cascade. Phytomedicine. 34,154–161.
32. Turgut, F., Bayrak, O., Catal, F., Bayrak, R., Atmaca, A. F., Koc, A., Akbas, A., Akcay, A., Unal, D., 2008. Antioxidant and protective effects of silymarin on ischemia and reperfusion injury in the kidney tissues of rats. International Urology and Nephrology, 40(2), 453–460.
33. Vargas-Mendoza, N., Madrigal-Santillán, E., Morales-González, Á., Esquivel-Soto, J., Esquivel-Chirino, C., García-Luna y González-Rubio, M. G., Gayosso-de-Lucio, J. A., & Morales-González, J. A., 2014. Hepatoprotective effect of silymarin. World J. Hepatol. 6(3), 144–149.
34. Wang, S. wei, Xu, Y., Weng, Y. yuan, Fan, X. yu, Bai, Y. feng, Zheng, X. yan, Lou, L. jun, Zhang, F., 2018. Astilbin ameliorates cisplatin-induced nephrotoxicity through reducing oxidative stress and inflammation. Food and Chemical Toxicology. 114, 227–236.
35. Zaulet, M., Kevorkian, S. E. M., Dinescu, S., Cotoraci, C., Suciu, M., Herman, H., Buburuzan, L., Badulescu, L., Ardelean, A., Hermenean, A., 2017. Protective effects of silymarin against bisphenol A-induced hepatotoxicity in mouse liver. Experimental and Therapeutic Medicine. 13(3), 821–828.